canceldeath
Sign in

Abolere mortem

What actually changed in longevity science

Research worth understanding. News worth reading. A clearer view of living longer.

New here? Take the guided tour →

What matters now

Important findings, useful explanations, and setbacks worth knowing about.

All stories →

10 stories from the past 72 hours. Older stories keep their original dates. Ranking reflects relevance, recency and reader interest—not proof of benefit.

Longevity news

News, research and the studies that currently shape the longevity chart—all in one stream.

  4. Research affecting the chart· PubMed

    Combined lifestyle factors, all-cause mortality and cardiovascular disease

    Published 2020Observational researchGeneral adult evidence
    Directly changes the Combined lifestyle chart input

    74 studies; 2,584,766 participants in the all-cause mortality analysis.

    Study scope and limits

    Adults in prospective cohorts; populations and lifestyle definitions varied.

    Healthiest versus least-healthy combinations of smoking, activity, diet, weight and alcohol factors.

    Observational association, with residual confounding and heterogeneous lifestyle scores. Not the effect of changing an average person’s habits. Alcohol in the score is not a recommendation to drink.

    Read the study · PubMed ↗
  7. Research affecting the chart· PubMed

    Associations Between Exercise Training, Physical Activity, Sedentary Behaviour and Mortality

    Published 2025Observational researchGeneral adult evidence
    Directly changes the Physical activity chart input

    Umbrella review of meta-analyses; equivalent hazard ratio for leisure-time physical activity.

    Study scope and limits

    Adults in the self-reported leisure-time physical activity syntheses.

    Higher versus lower self-reported leisure-time physical activity; contrasts vary across studies.

    Authors classify the association as suggestive evidence. Self-report, residual confounding and overlapping reviews limit interpretation. Replaces the combined lifestyle estimate rather than stacking on it.

    Read the study · PubMed ↗
  10. Research affecting the chart· PubMed

    Efficacy and safety of more intensive lowering of LDL cholesterol

    Published 2010Randomized researchCardiovascular prevention trial populations
    Directly changes the Statins chart input

    CTT individual participant meta-analysis of 26 trials; about 170,000 participants overall.

    Study scope and limits

    Participants enrolled in randomized LDL-lowering trials, with varied cardiovascular risk.

    Per 1 mmol/L lower LDL cholesterol, across statin versus control and more- versus less-intensive regimens.

    Mortality rate ratio is treated as a proportional hazard multiplier in this model. Trial populations and LDL changes differ; not a longevity estimate for healthy people or a prescribing recommendation.

    Read the study · PubMed ↗
  13. Research affecting the chart· PubMed

    Cardiovascular and Kidney Outcomes and Mortality With Long-Acting GLP-1 Receptor Agonists

    Published 2025Randomized researchType 2 diabetes trial populations
    Directly changes the GLP-1 agonists chart input

    10 randomized trials; 71,351 participants.

    Study scope and limits

    People with type 2 diabetes in large cardiovascular and kidney outcome trials.

    Long-acting GLP-1 receptor agonist versus placebo, on top of trial background care.

    Class-level synthesis in type 2 diabetes; not transferable to healthy adults, every agent, or lifelong use. Trials already include other care, so combining effects can double-count benefit.

    Read the study · PubMed ↗
  15. Research affecting the chart· journals.plos.org

    SGLT2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes

    Published 2023Randomized researchChronic kidney disease trial populations
    Directly changes the SGLT2 inhibitors chart input

    Systematic review of 14 randomized trials; all-cause mortality is a secondary endpoint.

    Study scope and limits

    People with chronic kidney disease, with or without type 2 diabetes.

    SGLT2 inhibitor plus standard therapy versus placebo or standard therapy.

    The 14 trials cover the review as a whole, not necessarily this endpoint. Kidney disease populations differ from the reference life table. Background treatment overlaps with other selections.

    Read the study · journals.plos.org ↗
More stories →

Find topics to follow

Explore a topic, read its evidence, and follow future updates.

Epigenetic clocks →Metformin →Senolytics →Smoking cessation →Exercise →SGLT2 inhibitors →Klotho →Air quality →